Mototsugu Tanaka

Has grant

Associate Professor

Niigata University Medical and Dental Hospital

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Causes and measures for delayed orphan drug development

Open Date: 2022-04-01

Close Date: 2026-03-01

Grant: Close

Current status and issues of drug lag in Japan

Open Date: 2021-04-01

Close Date: 2026-03-01

Grant: Close

Investigation of neutrophil extracellular trap degradation products using a new model of Streptococcus pyogenes tonsillitis.

Open Date: 2017-04-01

Close Date: 2021-03-01

Grant: Close

Identification and functional analysis of neutrophil extracellular traps degradation product in Streptococcus pyogenes infections.

Open Date: 2015-04-01

Close Date: 2017-03-01

Articles (10)

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Yasuhiro Fujiwara

Chief Executive

Pharmaceuticals and Medical Devices Agency

JAPAN

View details

Ilfita Sahbudin

University of Birmingham

UNITED KINGDOM

View details

Mutsuhiro IKUMA

Pharmaceuticals and Medical Devices Agency

JAPAN

View details

Masatoshi Miyakoshi

Associate Professor

University of Tsukuba

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mototsugu Tanaka

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

Conditional early approval for new drug applications in Japan: Current and emerging issues

Aortic arch calcification affects causes of death in patients on hemodialysis: a retrospective cohort study

Effluent N‐terminal expressed in renal cell carcinoma/mesothelin predicts increased peritoneal permeability in patients undergoing peritoneal dialysis

Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes

Achievements and challenges of the Sakigake designation system in Japan

Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan

The PMDA’s view on the limited pipeline of nephrology drugs in Japan

The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia

A bacterial small RNA regulates the adaptation of Helicobacter pylori to the host environment.

Ultrafiltration volume by once‐weekly hemodialysis is a predictor of technique survival of combination therapy with peritoneal dialysis and hemodialysis

Collaborators (4)

Yasuhiro Fujiwara

Ilfita Sahbudin

Mutsuhiro IKUMA

Masatoshi Miyakoshi

Make your next move.